Lhasa

Lhasa Limited is a not-for-profit educational charity dedicated to enabling informed decision making on chemical safety. The organisation develops cutting-edge in silico software solutions and facilitates precompetitive data-sharing initiatives that support risk assessments across the pharmaceutical, cosmetics, and chemistry industries. Driven by the principle of shared knowledge, shared progress, Lhasa's technology is designed by scientists, for scientists, in close collaboration with industry stakeholders and regulators.

Lhasa is committed to enabling scientists to make better predictions on the safety of drugs, chemicals, and cosmetics by using existing data more effectively and advancing computer-aided reasoning and information systems. As an educational charity, the organisation provides public benefit by reducing the need for animal testing, streamlining the drug development process, and safeguarding human health.

In Silico Software Solutions

• A suite of in silico software tools designed to support chemical safety assessments across pharmaceutical, cosmetic, and chemical sectors.
• Solutions are developed to align with member needs and regulatory expectations, ensuring scientific rigour and compliance relevance.
• Meteor supports confident metabolite identification and metabolite toxicity assessment.
• Tools for mutagenicity and genotoxicity assessment using complementary (Q)SAR approaches, helping scientists strengthen their safety evaluations.
• LCDB Plus, a recently launched product powered by over 4,000 carcinogenicity structures, provides centralised decision support for carcinogenicity assessments.
• Capabilities supporting ICH Q3D compliance using regulatory-aligned consortium data, helping organisations avoid unnecessary testing.

Precompetitive Data Sharing Initiatives

• Lhasa facilitates collaborative, precompetitive data-sharing projects that give members access to high-quality proprietary data to support their risk assessments.
• Data sharing programmes are designed to complement in silico modelling by providing robust, industry-contributed datasets that improve prediction confidence.
• Initiatives cover areas including genotoxicology, nitrosamines, elemental impurities, and carcinogenicity, among others.
• The organisation hosts dedicated webinar series, such as the Lhasa Nitrosamine Webinar Series 2026, to support knowledge exchange across the industry.

Scientific Focus Areas

• Genotoxicology research and innovation, recognised through initiatives such as the Lhasa Young UK Scientist Award.
• Toxicology risk assessment, including problem-solving approaches for complex safety challenges.
• Nitrosamine risk assessment, with dedicated resources and community engagement.
• Carcinogenicity and mutagenicity evaluation supported by large, curated structural databases.
• Elemental impurity assessment aligned with regulatory frameworks such as ICH Q3D.

Organisation and Values

• Lhasa operates as a not-for-profit organisation, reinvesting in scientific development and member services rather than commercial profit.
• Teams are multidisciplinary, combining diverse scientific and technical skills to develop world-class software solutions.
• The organisation fosters a culture of diversity and inclusion, believing that better discussions, decisions, and outcomes arise from an empowered and diverse workforce.
• Lhasa has been shortlisted for the Lush Prize 2026 – Science, recognising its contributions to advancing non-animal approaches in safety science.

Through its unique combination of collaborative software development, precompetitive data sharing, and a not-for-profit mission, Lhasa Limited continues to advance the science of chemical safety assessment, supporting regulators, pharmaceutical companies, cosmetics manufacturers, and the broader chemistry industry in making well-informed, evidence-based decisions.